Viewing Study NCT02193503


Ignite Creation Date: 2025-12-24 @ 7:41 PM
Ignite Modification Date: 2026-01-05 @ 6:18 PM
Study NCT ID: NCT02193503
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2023-09-28
First Post: 2013-08-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: MVX-ONCO-1 in Patients With Solid Tumor
Sponsor: Maxivax SA
Organization:

Study Overview

Official Title: An Open Phase I Clinical Study Assessing Safety and Tolerability of MVX-ONCO-1 in Patients With Solid Tumor Who Are Not/Not Any Longer Amenable to Standard Therapy
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2023-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objectives are to assess the safety and tolerability of 6 vaccine doses of MVX-ONCO-1, administered sub-cutaneously (injections and capsules implantations), in patients with advanced metastatic solid tumor in progression who are not or not any longer amenable to any standard therapy of their tumour disease.
Detailed Description: Endpoints:

Primary: To assess safety parameters including adverse and serious adverse events (incidence, causality, severity), local and systemic tolerance to the administered study treatment, changes in laboratory values and vital signs in patients with solid tumor; Secondary: to measure some tumor responses in using imaging technique, serological tumor markers, immune monitoring and metabolic monitoring.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: